


Neuroscience and Mental Health

Processing thought processing




Dawn Collins
Warwick Medical School
dawn.collins@warwick.ac.uk

Dysfunction of the nervous system



- Occurs for a number of reasons:
 - Damage by trauma or disease*
 - Neurons lose ability to produce transmitters
 - Neurons over- or under-produce transmitters
 - Neurons fail to recognise transmitters
 - Effector organs fails to respond
- Can manifest as:
 - **Loss:** of sensation or function
 - **Gain:** appearance of new feature
 - **Change:** alteration in behaviour/personality of perception

Das ist dz an
der instrument / vñ
das dyenet mer ob
en vff dz haubt / daß
sinst darnebi / oder
binden. Darumb dz
es mit dreyte gleych
hat / als dz nechst in
strumet hie vor ver
zeychet. Vnd dyen
et auch / wann die
hyrnschal jngechla
gen ist / das man sye
mit disē instrument
wider vffschraub.




*If the cell body is intact, regeneration of neurons may occur.


The Central Nervous System




The Brain




Side View



Coronal section




Sagittal section




View of base of brain

The Cerebral Lobes


- Frontal – Motor, higher cognition
- Parietal – Sensory
- Occipital – Vision
- Temporal – Language
- Insula – Emotional control
(Limbic system – Learning/Memory)



© 2002 Sinauer Associates, Inc.



© 2002 Sinauer Associates, Inc.



© 2002 Sinauer Associates, Inc.

The Cortical Association Areas

Prefrontal cortex

Involved in higher cognition, reasoning, rationale, motivation and moods; 'who we are'
Damage causes affective and cognitive disorders

Central Sulcus

Frontal Lobe

Parietal Lobe

Temporal Lobe


Occipital Lobe

Parieto-occipito-temporal cortex




Interacts with primary sensory and motor areas
Damage causes the majority of sensory, motor, proprioceptive and dissociation disorders

Limbic Association Areas

Involved in learning and memory formation, spatial perception, motivation and emotional processing
Damage causes affective and cognitive disorders




3D Images



Prefrontal cortex and 'higher cognition'

Pre-frontal cortex refers to any region of the frontal lobe preceding the motor areas

- Main roles: integration and decision making
- Responsible for personality
- Famous case: Phineas Gage



Prefrontal Cortex

- 'Higher control,' involved in:

- Restraint behaviours


- Concentration
- Judgement
- Foresight
- Focus

- Initiating behaviours


- Motivation/Drive
- Spontaneity
- Personality
- Curiosity

- Ordering behaviour

- Planning/Sequencing
- Working memory
- Abstract thought
- Perspective



© 2002 Sinauer Associates, Inc.



© 2002 Sinauer Associates, Inc.


Limbic system

- Group of deep cortical and subcortical structure, includes:

- Hippocampus
- Amygdala
- Nucleus accumbens
- Cingulate gyrus
- Mammillary body
- Thalamic and hypothalamic nuclei
- Entorhinal and perirhinal cortices

- Involved in:

- Memory
- Learning
- Perception (sensory, emotional and spatial)
- Motivation




- Links to Insula, the hidden lobe, moderates emotional responses and links limbic to homeostatic regions, also contains taste centre

Circuitry within the limbic system



- Interplay within limbic system, and cortex aids integration relevant to:

- Arousal
- Learning
- Memory
- Emotions
- Higher cognition





Reward and Fear

- Regions of the limbic system are implicated in positive and negative emotions
- Nucleus accumbens is linked to the reward pathways
- Amygdala linked to negative emotions
- The uncinate fasciculus links amygdala to PFC
- The insula sets the threshold of response
- Hippocampus put everything into context and remembers it



Regional Interactions

- Large tracts between and within frontal lobes and limbic system allow for intricate 'high level' processing
- Also link sensory, motor and basic biophysical information
- Insula sets emotional thresholds
- Changes in tract activity detected in psychotic episodes and major depressive disorders and bipolar disorders




Cerebral activity and attention

Large scale networks involved in control of attention and arousal

3 main attentional Circuits:

- Default mode network (non-specific, self-reference)
 - Medial temporal cortex
 - Medial prefrontal cortex
 - Posterior cingulate gyrus
- Dorsal attentional network (orienting and processing)
 - Dorsolateral prefrontal cortex
 - Posterior parietal cortex
 - Corpus striatum
- Ventral attentional network (engagement and activation)
 - Basolateral amygdala
 - Lateral and inferior frontal cortex
 - Temporoparietal cortex
 - Ventral striatum

Default Mode Network



Dorsal Attentional Network



Ventral Attentional Network



So why is neuroscience important?

We need to understand how the brain *functions* physiologically at a number of levels

- Cellular/subcellular
- Communication
- Coordination
- Patterns
- Behaviour



...To be able to apply this to disorders

...To develop effective treatments with minimal side-effects



Cell Types in the nervous system


- **Neurons**
 - Principal cells
 - Interneurons
- **Glia**
 - Astrocytes
 - Ependymal cells
 - Microglia
 - Oligodendroglia
 - Schwann cells



Synapses


- Chemical

- Vesicles releases from presynaptic terminal
- Act on receptors in postsynaptic terminal
- Major drug target



- Electrical

- Gap junctions
- Small molecules and current
- 'low-pass filter'
- Synchrony
- Up-and-coming drug target



Transmitters

- **Neurotransmitters**

- Used by neurons for rapid cell-cell communication
- Binds to receptor
- Excitatory propagates the signal onward
- Inhibitory blocks onward propagation


- **Neuromodulators** (and other modulatory substances):

- Found in vesicles (or not), co-localised with NT
- Act on receptors or membranes to indirectly alter neuronal activity
- Changing sensitivity or kinetics of NT receptor
- Also act on glial cells

- Most disorders linked to change in transmitter efficacy

- Some result from single transmitter alteration, usually more than one pathway will be affected

Neurotransmission in the nervous system		
Type	Name	Main Role
Neurotransmitter	Glutamate	Excitatory
	GABA	Inhibitory
	Aspartate	Excitatory
	Glycine	Inhibitory
	Acetylcholine	Neuro-muscular Junction
	Adrenaline	Stress/arousal
	Noradrenaline	Stress/arousal
	Dopamine	Motivation/Motor function
Neuromodulators	5-HT (serotonin)	Homeostasis
	Histamine	Arousal
	Neuropeptide Y	Appetite
	Substance P	Pain
	Vasopressin	Osmoregulation
Other transmitters	Somatostatin	Growth
	Anandamide	Endogenous Cannabinoid
	NO	Modulatory, not found in vesicles
	CO	Modulatory, not found in vesicles
	Adenosine	Modulatory, not found in vesicles
ATP	Modulatory, not found in vesicles	




Receptors in the nervous system

Ionotropic – linked to ion channels

Metabotropic – G-protein linked (aka GPCR)

- Receptors transmitter specific
- Some transmitters act on both types
- Drugs generally targeted at one specific subtype of receptor
- Drugs targeted at receptors sometimes too strong, now developing subunit specific agonists
- Polyvalent, non-selective (or 'dirty' drugs) act on multiple sites
- Think about where else the drug could be acting, that's where you'll see problems occurring



Excitation and Inhibition

Major Excitatory transmitter - **Glutamate**

Major Inhibitor transmitter – **GABA**

- Inhibition responsible for coding of activity
- Plasticity changes strength at neuronal level
- Synchrony gives strength at network level

Coding of Activity

- Excitatory neurons have regular firing in absence of inhibition
- Inhibitory input sculpts this to give patterns (coding)
- Coding carries the information and can be read, like morse code
- Some drugs that increase firing can lead to loss of coding, and psychological side effects


Glutamate Neuron Firing



GABA Neurons




Excitatory Neuronal Firing



What mechanisms are involved in pathogenesis of neuronal and psychological disorders?

- Altered neuronal activity
- Altered synchrony
- Cellular changes
- Subcellular change
- Genetic composition




<http://g.psychcentral.com/news/u/2010/09/neuron-mind-2.jpg>

The aim is to restore balance!

Pathway Interactions

- Activation of one class of neuron often has knock-on effects on other pathways
 - NA levels can directly alter 5HT activity
 - 5HT levels can alter DA activity
 - DA levels can alter Ach Activity
 - Ach levels can alter GABA activity
 - And vice-versa for all!



- It's a tangled web indeed!



Inflammation

- Inflammatory mediators lead to:
 - Microglia activation
 - Cell dysfunction
 - Cell death


- Leads to spectrums of disorders



Pasternak et al. (2016) 'In vivo imaging of neuroinflammation in Schizophrenia.' Schiz. Res., 173, 200-212

Neurogenesis




- Changes in arborisation
- Changes in synapse structure
- Altered receptor number
- Restored by drugs



Neurodegeneration

- Cellular – death of cell body (no regeneration possible)
 - Parkinson's
 - Alzheimer's
 - ? Schizophrenia
- Axonal – dying back of axon proximal to cell body (some regeneration possible). Wallerian – distal degeneration of axon and myelin (generally trauma induced)
 - Diabetic neuropathy
 - Nerve compression
- Myelin – loss of oligodendroglial/schwann cells affecting conduction velocity
 - Multiple Sclerosis (central)
 - Guillain Barré (peripheral)

* Neurofibrillary Tangle (tau)
↑ Neuritic Plaque (β-amyloid)
↑ Diffuse Plaque



Scan from MS patient

Stages of Wallerian Degeneration

How can you study Psychiatric disorders

- Human Studies
- Animal Studies
 - Behaviour
 - Electrophysiology
 - In vivo
 - In vitro
 - Molecular



NPSA home Site map Text size: Smaller | Normal | Larger

Keywords
[consent form] Search

NHS
National Patient Safety Agency
National Research Ethics Service

Home | About us | News and publications | Training and events | Applications | Patients and the public | REC community | Useful links | Contact us

Facilitating and promoting ethical research
Protecting participants' rights, dignity and well-being

Information for applicants	REC community	NRES announcements
<ul style="list-style-type: none">Find your local RECGuidanceHow to apply	<p>Statement of patient</p> <p>Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of page 2 which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask - we are here to help you. You have the right to change your mind at any time, provided you have signed this form.</p> <p>I agree to the procedure or course of treatment described on this form.</p> <p>I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate experience.</p> <p>I understand that I will have the opportunity to discuss the details of anaesthesia with an anaesthetist before the procedure, unless the urgency of my situation prevents this. (This only applies to patients having general or regional anaesthesia.)</p> <p>I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health.</p> <p>I have been told about additional procedures which may become necessary during my treatment. I have read below any procedures which I do not wish to be carried out without further discussion.</p> <p>Patient's signature Name (PRINT)..... Date</p> <p>A witness should sign below if the patient is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign (see notes).</p> <p>Signature..... Date</p> <p>Confirmation of consent (to be completed by a health professional when the patient is ready for the procedure. If the patient has signed the form in advance)</p> <p>On behalf of the team treating the patient, I have conferred with the patient that she has no further questions and wishes the procedure to go ahead.</p> <p>Sign:..... Date</p> <p>Name (PRINT)..... Job title</p> <p>Important notes: (tick if applicable)</p> <p><input type="checkbox"/> See also advance checklist/visit with (eg. anaesthetist's witness form)</p> <p><input type="checkbox"/> Patient has withdrawn consent (ask patient to sign note here)</p> <p>3</p> <p>In which I believe she can understand..... to the best of my ability and in a way</p> <p>Signature..... Date</p> <p>Name (PRINT).....</p>	<p>NRES announcements</p> <p>Statement of National Research Ethics Service</p> <p>Statement of National Research Ethics Service</p> <p>Statement of National Research Ethics Service</p>

Top copy accepted by patient: yes/no (see mp)

Cellular Research Techniques


- In-vitro
 - Receptor expression
 - Receptor modification
 - Pharmacology
 - Genetic modification
 - Subcellular mechanisms
- Quick turnaround
- Controllable

Totally Unrealistic



Biomarkers

- Aims to identify potential markers than can indicate predisposition to disorders
 - Activity – metabolic/neuronal
 - Genetic
 - Epigenetic
 - Protein




Genetic Profiling

Genetic composition may lead to predisposition for disorders

May also affect likelihood of response to treatment

Examples include:

- 5HT receptor subtypes
- DA receptor subtypes
- GABA receptor subunit variations
- GAD enzymes [synthesizes GABA]



Inconclusive at present and can't account for environmental factors

Current Drug R&D Targets

Reprofiling

NeuroTransmitters


5HT
Dopamine
Noradrenaline
Glutamate
GABA

Neuromodulators

Cannabinoids
Peptides

Subunit specific drugs

Benzodiazepines




GABA_A receptor subunit distribution in the amygdala.
From: Marowsky et al (2004) European Journal of Neuroscience, 20, 1281–1289.

Placebo Effect

- 30% of patients respond to placebo
- Can change neuronal activity levels
- Different effects to ADs



- Works even if told!



What's psychotherapy doing?

- New learning?
- Overwriting/depressing old learning?
- Altering brain activity frequencies?
- Desensitizing?

Or just coping?



CBT treatment of phobias

Psychosis

- Broad range of mental disorders (ICD F20-29: Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders) with symptoms including:
 - hallucinations (seeing, hearing, smelling, tasting or feeling things that are not there)
 - delusions (false and unshakable beliefs)
 - Serious defects in judgement (reasoning, evaluating objectively)
 - Disturbed cognitive processing (thinking)
- Symptoms may be constant or intermittent depending on the underlying cause
- Sufferers inhabit a world of their own making
- Schizophrenia most common and most severe form (c.1%)



Hallucinations

Hallucinations are perceptions in the absence of external stimuli.

Common hallucinations include:

- Auditory hallucinations – hearing voices/sounds
- Tactile/somatic/gustatory hallucinations – feeling bodily sensations
- Visual hallucinations - seeing patterns/images
- Olfactory hallucinations - smelling a foul or pleasant odour



<http://www.sleepcare.com/index.php/sleep-hallucinations/>



Fuseli: The nightmare

Causes of Hallucinations

There are many causes of hallucinations, including:

- Delirium
- Dementia – e.g. Dementia with Lewy Bodies (DLB)
- **Psychiatric disorders, e.g. Schizophrenia and psychosis**
- Drugs, alcohol or medications
- Epilepsy – focal seizures
- Narcolepsy
- Visual impairment – Charles Bonnet syndrome


In some cases, hallucinations are normal:

- Part of the grief process
- Hypnagogic (falling asleep) and hypnopompic (waking) hallucinations



Charles Bonnet Syndrome

- Commonly seen in people with severe visual impairment
- Brain 'filling in' gaps
- Visual only
- Often animals and people
- Can be scary!
- Patient knows they are not real




Cerebral Activity and Hallucinations

? Spontaneous activation of sensory centres

Activity in fMRI shows activity as if the hallucination is real

Hallucinatory activity overrides actual sensory input


Temporary disconnect between cortical and thalamic regions



Auditory Hallucinations: Shergill et al. (2000) Arch. Gen. Psych., 57, 1033-1038


Circuit involved in Psychosis

- Prefrontal cortex – dorsolateral and ventrolateral
- Anterior cingulate gyrus
- Basal ganglia – **striatum**
- Hippocampus
- Cerebellum



Transmitters involved in psychosis

- Two main transmitters:
 - Dopamine
 - Acetylcholine
- Others include:
 - Serotonin
 - Glutamate
 - Histamine
 - Noradrenaline




What role does Acetylcholine play in arousal?

- Peripherally controls ANS and muscle function (NMJ)

- Centrally involved in:

- Alertness
- Arousal
- Attention
- Sleep
- Memory
- Learning




© 2002 Sinauer Associates, Inc.

- Acetylcholine (ACh) modulates a number of transmitter pathways, including dopamine

Dopamine Pathways


4 main pathways:

- **Nigrostriatal** - movement
- **Mesolimbic** – mood, memory
- **Mesocortical** – mood, higher cognition
- **Tubero-hypophyseal** – inhibits prolactin release



Link between DA and ACh

- ACh can modulate activity in dopamine pathways (and vice-versa)
- This will also have knock-on effects on other monoamines, NA and 5HT
- ACh and DA neurons in striatum modulate PFC and are abundant in the hippocampus




And environmental factors?

- Gut-brain axis?
- Gut microbiome?
- Cannabis use
- Stress
- Combinations key!

Moore et al. (2007) 'Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.' *Lancet*, 370, 319–28.

Severance et al. (2016), Autoimmune disease, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling.' *Schiz. Res.* 176, 23-35




Foster and McVey Neufeld (2013) 'Gut-brain axis: how the microbiome influences anxiety and depression.' *Trends Neurosci.*, 36, 305-312

Stages of Psychosis

- **Prodrome:** early signs of impending onset of psychosis, e.g. changes in feelings, thoughts, disconnection
- Any person exhibiting prodromal stage will develop psychosis

Phases of Psychotic Disorder



Treatment of Psychosis

- **Prodromal**
 - Referral
 - **Specialist assessment**
 - Interventions to prevent onset
 - Psychological interventions
 - CBT
 - Family intervention
 - Interventions to treat anxiety/stress/PTSD and/or alcohol/drug misuse
- **First episode**
 - **Early intervention team**
 - Psychological interventions
 - Pharmacological interventions – oral antipsychotic, low dose trial 4-6wks
 - Regular monitoring
- **Recurrent episodes**
 - Psychological interventions
 - Pharmacological – antipsychotics and/or mood stabilisers
 - Regular health monitoring
 - Support network – self-help groups
- **Acute episode**
 - **Crisis resolution team**
 - Antipsychotics
 - Benzodiazepines (rapid tranquilisation only)



Antipsychotics

First and second generation

Need therapeutic dose to reach 60% occupancy at D₂ for effective response



First Generation (aka classical/typical)

- Primarily potent D₂ antagonists
- Extrapyramidal effects high
- Low efficacy
- 30% non-responders

Second Generation (aka atypical)

- Primarily multiple actions 5HT₂ & D₂ & others
- Reduced extrapyramidal effects
- Better at treating negative symptoms
- Higher efficacy

Various Binding Properties of Conventional Antipsychotics



Atypical antipsychotic


Drug	D ₁	D ₂	D ₃	D ₄	α ₁	α ₂	H ₁	ACh	5-HT ₁	5-HT ₂	5-HT _{2A}
Clozapine	++	+	?	+	+++	+++	+++	++	+	++	+
Risperidone	+	+++	?	+	+++	+++	+	-	+	-	+++
Olanzapine	++	+++	+	+	++	+	+++	+	-	++	++
Quetiapine	+	++	+	-	+++	+	+++	-	-	+	+++
Aripiprazole	+	++++	?	?	-	-	-	-	++	?	+++
Ziprasidone	++	+++	++	?	++	-	+	-	++	?	+

D=dopamine; α=alpha-adrenergic; H=histamine; ACh=acetylcholine; 5-HT=5-hydroxytryptamine (serotonin); +++=very high affinity; ++=high affinity; +=moderate affinity; +=low affinity; -=negligible affinity; ?=unknown affinity.

Side Effects

5 main groups of side-effects

- Extrapyramidal (EPS)
- Cardiovascular – increased QT interval
- Metabolic – weight gain/diabetes
- Hormonal – increased plasma prolactin
- Other – includes psychiatric



Extrapyramidal (~75% of cases):

- Parkinsonism symptoms

Also:

- Dystonias
- Akathisia
- Sedation
- Cardiovascular
- Prolactin elevation
- TARDIVE DYSKINESIA

2nd Generation

- Fewer EPS
- Cholinergic effects

	Extrapyramidal	Sedation	Weight gain	Hyperglycaemia	Anticholinergic	Orthostatic hypotension
Atypical antipsychotics						
Risperidone	●●	●● initially	●●	●●	●	●● initially
Quetiapine	●*	●●●	●●	●●●	●●	●●
Olanzapine	●	●●●	●●●	●●●	●●●	●
Clozapine	●	●●●	●●●	●●●	●●●	●●
Amisulpride	●●*	●	●	●	●	●
Aripiprazole	●	●	●	●	●	●
Ziprasidone	●	●●	●	●	●	●●
Typical antipsychotics						
Haloperidol	●●●	●	●●	●●	●	●
Chlorpromazine	●●	●●●	●●●	●●●	●●●	●●●

Approximate frequency of adverse effects: ● (<2%) = negligible or absent; ● (>2%) = infrequent; ●● (>10%) = moderately frequent; ●●● (>30%) = frequent. * rarely a problem at usual therapeutic doses

Tardive Dyskinesia

Typical symptoms

Disabling involuntary movements: tongue protruding, choreiform movements, grimacing, twisting


In many cases IRREVERSIBLE

- Occurrence ~25% of Cases
- Increases with length of exposure
- Remits spontaneously in ~30%
- Anticholinergic use stopped immediately
- Vitamin E & B6, Benzodiazepines, β -blockers can help
- Switch to 2nd generation antipsychotic



Neuroleptic Malignant Syndrome

- Rare but potentially fatal side-effect
- Caused by over-activation of ANS/metabolic pathways:
 - Hyperthermia
 - Altered level of consciousness
 - Pallor
 - Sweating
 - Tachycardia
 - Fluctuating BP
 - Muscle rigidity
 - Urinary incontinence
- No effective treatment, try:
 - Stop antipsychotic use
 - Bromocriptine (dopamine agonist)
 - Dantrolene (muscle relaxant)



<http://epomedicine.com/clinical-cases/neuroleptic-malignant-syndrome-nms-approach/>

Benzodiazepines

Act on GABA_A receptor (γ subunit) to increase activity
Reduces neuronal transmission by enhancing inhibition

Commonly used benzos:

- Diazepam (valium)
- Midazolam (sedative)
- Lorazepam (status epilepticus)
- **Flumazenil** (antagonist)

Benzodiazepines

Positive Allosteric Modulators (co-agonists) of GABA_A receptors

Benzodiazepines, e.g. Midazolam, bind to the γ -subunit of GABA_A receptors, working together with GABA to increase the opening of the channel allowing more chloride entry into the cell. This hyperpolarises the cell reducing the likelihood of action potential firing.



Summary

- Whilst we know a lot about the mechanisms underlying psychiatric disorders, treatments have not progressed as rapidly as the knowledge
- No one research model encompasses all of the human symptoms
- Human studies can be difficult and often inconclusive
- Assuming everyone is different means we'll probably never know the whole truth